MoonLake Immunotherapeutics (MLTX) shares plunged after the company reported results from its Phase 3 trials for sonelokimab in hidradenitis suppurativa. The VELA-2 study missed its main goal, ...

CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

KOHLER — The Eastern Wisconsin Conference was center stage on Thursday, Sept. 4 with all eight teams in action against each other. And what figured to be a back-and-forth contest in Kohler was ...

A phase 3 trial of Sanofi’s eczema prospect amlitelimab has hit its primary and key secondary endpoints. Yet, with the data falling short of analyst expectations, shares in the company opened down 9% ...

YAKIMA, Wash. — The next phase of the 72nd Avenue and Washington Avenue roundabout project begins Monday, July 28th. This third phase will require closing the intersection to all traffic 24/7 from ...

Treatment with AD109 resulted in a clinically meaningful and statistically significant reduction in airway obstruction compared with placebo. Topline results were announced from a second phase 3 trial ...

The GCAptAIN study, which included patients with newly diagnosed or relapsing GCA, missed its primary endpoint of sustained remission at week 52. Topline results were announced from a phase 3 study ...

Apple CarPlay Set Up: Tips and Tricks to Get Going ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The mRNA shot stacked up well against a licensed ...

A Phase 3 clinical trial testing the experimental daily oral treatment ralinepag in people with pulmonary arterial hypertension (PAH) has completed enrollment. The ADVANCE OUTCOMES trial (NCT03626688) ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 ...